

## **Genomtec S.A. wants the Shareholders to participate in the benefits of the potential M&A transaction to the largest possible extent**

**The Management Board of Genomtec S.A., a medical technology company, has passed a resolution to determine how to distribute funds from a potential technology sale. The Company's intention is for shareholders to benefit from a potential M&A transaction to the fullest extent possible. As part of its ongoing review of strategic options, Genomtec is working with a transaction advisor, Clairfield Partners LLC, based in New York.**

In accordance with the adopted resolution, the Management Board of Genomtec will take actions to benefit the Company's Shareholders from the potential sale of technology to the largest possible extent, including in particular in the form of acquisition by a potential buyer of 100% of Genomtec shares or allocation for payment to Shareholders of the entire profit obtained by the Company as a result of the potential sale of technology.

*- We decided to adopt a resolution on determining the method of distributing funds from the potential sale of technology, because we want to give current and future shareholders of Genomtec clear information that all activities carried out by the company are aimed at maximizing profit for shareholders. For this purpose, we also decided to issue shares. The funds raised will allow us to: demonstrate the potential of our technology in the field of oncological diagnostics, complete clinical trials and validate the Genomtec ID platform in leading medical centers in Europe. We are convinced that our actions will significantly increase the value of our technology – said Miron Tokarski, President, Co-founder and significant Shareholder of Genomtec S.A.*

On March 27<sup>th</sup>, the General Meeting will be held, at which the shareholders of Genomtec will decide on the issue of up to 1,237,000 series M shares and the issue of up to 400,000 shares from the authorized capital to a significant shareholder Leonarto Funds SCSp or an entity indicated by the fund.

As part of Genomtec's review of strategic options, in January Genomtec received from the German company Dennemeyer Consulting GmbH a valuation of the Company's intellectual property portfolio. In accordance with the DIN/ISO 77100 standard adopted by Dennemeyer, covering Genomtec's possession of patents and patent applications and the conversion of all patent applications into patents, as well as the 14-year protection period of the entire IP (intellectual property) portfolio, the fair value of Genomtec's intellectual property was estimated at EUR 191.336 million gross. Average term of patent protection of petitioners held by Genomtec is more than 15 years. The Genomtec technology is protected by 10 patents in Europe, the USA, Brazil and Japan, and over 20 patent applications on global markets.

---

### **About Genomtec:**

Genomtec is a MedTech company specializing in the development of advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for fast and precise molecular analysis outside the laboratory environment without the need to involve qualified laboratory personnel. The solution uses microfluidic technology and proprietary patented SNAAT isothermal technology. The Genomtec technology is protected by 10 patents in Europe, the USA and Japan, and over 20 patent applications on global markets.

The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections

The company's registered office is located in Wrocław. Genomtec also has a branch in the UK, where part of the international research and engineering team is located.

More information is available on the shelf page: [www.genomtec.com](http://www.genomtec.com)

### **Media Contact:**

Kamil Majcher

NewTech Comm

[k.majcher@newtechcomm.pl](mailto:k.majcher@newtechcomm.pl)

+48 507 649 596

By gaining access to press releases ("Press Releases") of Genomtec S.A. with its registered office in Wrocław ("Company") and reading their content, you acknowledge and agree to be bound by the following reservations and conditions:

The Company's Press Releases are for promotional and informational purposes only and should under no circumstances constitute the basis for making a decision to purchase the Company's shares.

The Press Releases have been prepared by the Company for informational purposes only, and none of the provisions contained therein constitutes any recommendation regarding the purchase of shares, does not constitute an offer to sell the Company's securities or information on the terms of their acquisition or subscription constituting a sufficient basis for making a decision to purchase or subscribe for these securities, and none of the provisions contained therein constitutes investment advice, legal or tax, nor is it an indication that any investment or strategy is appropriate to the individual circumstances of the investor.

Investing in the Company's securities is associated with high risk inherent in equity capital market instruments and risks related to the Company's operations and the environment in which the Company operates.

All rights to the Press Releases and to their individual elements, including proprietary copyrights, are vested in the Company. In addition, the Company indicates that the reproduction, distribution, transmission or making available of the Press Releases may be subject to legal restrictions (restrictions and their scope may vary from jurisdiction to jurisdiction) and any person to whom the Press Releases are provided or otherwise made available should familiarize themselves with such restrictions and strictly comply with them. The Press Releases, or any part thereof, may not be distributed in the United States of America, Canada, Australia or Japan or to U.S. Persons.

Persons reviewing the Press Releases also represent that they are not covered by the applicable laws of any jurisdiction in which the display, distribution or publication of materials contained in the Press Releases would be prohibited or would require appropriate permission or permission.

The Press Releases are for informational purposes only and do not constitute an offer to sell securities or an offer to obtain an offer to buy securities or any other instruments or shares in the Company or any other undertaking.

The Press Releases also do not constitute an offer to cooperate on any other terms, or an offer to sell or an invitation to submit offers to buy, or subscriptions for shares of the Company or any other securities of either the Company or third parties. The content of the Press Releases does not constitute, and will not be incorporated by reference, any agreement between the Company and any third party, nor shall it give rise to any obligations of the Company, persons acting on behalf of the Company or persons to whom it is made available. Persons to whom the Press Releases are made available should not rely on them in connection with any contract, obligation, or intention of any other action relating to the Company.

The Press Releases do not contain a complete or complete financial or commercial analysis of the Company. The Press Releases do not represent a complete or comprehensive analysis of the Company's position or prospects. Press releases have been prepared with due diligence and attention to the quality of information contained therein, however, there is a risk of inaccuracies as well as omission of some information. Any decisions concerning the Company should be made on the basis of independently conducted analyses and research. Persons who have read the Press Releases bear full responsibility for their possible assessment of the Company's situation and forecasts of its future development.

In the event that the Press Releases contain forward-looking content or statements, including analyses regarding the possible or expected future financial or commercial results of the Company, each such statement or content is subject to risk. The risk referred to in the preceding sentence consists of both factors known and unknown to the Company. Due to the possibility of a significant number of unforeseen events and other factors that may cause the actual financial results of the Company as well as the situation in the industry in which the Company operates, to the extent that they contain statements regarding the future. Nothing in the Press Releases should be construed as a guarantee or assurance or commitment that the Company will achieve any particular financial or commercial performance in the future.

The Company, its members of its bodies and directors, as well as shareholders, advisors or representatives of the Company make no express or implied representations, warranties or warranties as to the accuracy, completeness, correctness of the information and content contained in the Press Releases, or that in no event can any such content or information mislead the recipient. The Press Releases and the content contained therein have not been verified by entities independent of the Company. To the fullest extent permitted by law, the liability of the persons indicated above for any statements, content or statements contained in the Press Releases is excluded, including for any damage that could be caused by compliance with these statements, content or statements by persons to whom the Press Releases have been made available.

No statement contained in the Press Releases results in any of the indicated entities incurring any obligation. The Company, members of its bodies and management as well as shareholders, advisors, representatives of the Company are exempt from liability for any consequences of the use of information, data or statements contained in the Press Release, or any part thereof, regardless of the manner and purpose of such use. All responsibility for the use of any information contained in the Press Releases rests with the person using such information. Any information, statement or analysis regarding the future may be changed by the Company or their representatives at any time without prior notice of such change. The Company, members of its bodies and management as well as shareholders, advisors, representatives of the Company are not obliged to update the Press Releases in the event of any changes or to provide the recipients of the Press Releases with any additional information.

Nothing contained herein or in the Press Releases constitutes any recommendation regarding the purchase of shares or any other action having equivalent effects on the Company's shares or any other securities. None of the presented information constitutes forecasts, including but not limited to financial forecasts, and should not be interpreted as forecasts. This document or the Press Releases have not been approved or verified in any way by the Polish Financial Supervision Authority, and their content has not been audited or approved by the Warsaw Stock Exchange. Investment in shares involves a number of investment risks, therefore investors should carefully and thoroughly familiarize themselves with the risk associated with the Company's operations and the environment, in which the Company operates.